Patent ID: 9549971
Date: 2017-01-24
CPC Classifications: A01K,A61K,A61P,C07K,C12N

Claim:
1. A method of reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis, comprising administering to the subject an EGFL8 antagonist, wherein EGFL8 has the sequence of SEQ ID NO:1 or SEQ ID NO:2, and wherein the EGFL8 antagonist is an anti-EGFL8 antibody or a fragment thereof which binds to EGFL8 and wherein the pathological condition is diabetic retinopathy, choroidal neovascularization (CVN), age-related macular degeneration (AMD), diabetic macular edema (DME), pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, retinal vein occlusion (RVO), central retinal vein occlusion (CRVO), branched central retinal vein occlusion (BRVO), corneal neovascularization, retinal neovascularization, retinopathy of prematurity (ROP), subconjunctival hemorrhage, hypertensive retinonpathy, neovascular glaucoma or immune rejection of transplanted corneal tissue.